A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.
from Reuters: Health News https://reut.rs/2KNzhr9
via IFTTT
from Reuters: Health News https://reut.rs/2KNzhr9
via IFTTT
إرسال تعليق